Mahmoud M. Elhady
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahmoud M. Elhady has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Manar Adel
Faculty of Clinical Pharmacy, Tanta University, Gharbia, Egypt
2 shared publications- Abdelrahaman G. Tawfik
Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City Utah USA
1 shared publication Abdelrahman Zidan
Emory Clinical Cardiovascular Research Institute, Emory University, Atlanta, USA
1 shared publication- Abdulrhman Helal
Faculty of Medicine, Benha University, Benha, Egypt
1 shared publication Ahmed Ebrahim
Cardiology Registrar, Ninewells Hospital, Dundee, Scotland
1 shared publication- Ahmed Hashem Fathallah
Faculty of Medicine, Minia University, Minia, Egypt
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1) , 965
Drug-coated balloons in coronary disease: meta-analysis comparing sirolimus- and paclitaxel-coated technologies
Drug-coated balloons (DCBs) are a key alternative to drug-eluting stents for coronary artery interventions, offering the advantage of drug delivery without
- 22 October 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1) , 965
Open AccessDrug-coated balloons in coronary disease: meta-analysis comparing sirolimus- and paclitaxel-coated technologies
Drug-coated balloons (DCBs) are a key alternative to drug-eluting stents for coronary artery interventions, offering the advantage of drug delivery without
- Open Access
- 1 July 2026
- Published by Springer Nature in Archives of Sexual Behavior
- Vol. 55 (7) , 3205-3221
Arabic Validation of the Problematic Pornography Consumption Scale: Psychometric Properties, Measurement Invariance, and Gender-Specific Network Analysis
Problematic pornography use (PPU) remains understudied in Arabic-speaking populations, partly due to the limited availability of culturally validated assessment tools. This study translated and validated the Arabic version of the Problematic Pornography Consumption Scale (PPCS) and examined gender-based differences in symptom structure. A total of 959 Egyptian university students who watched pornography at least once per week (65.1% male, 34.9% female) completed the Arabic PPCS, along with standardized measures of depression, anxiety, perceived stress, and problematic internet use. Confirmatory factor analysis supported the original six-factor model (CFI = 0.950, RMSEA = 0.075, SRMR = 0.031), with the scale demonstrating excellent internal consistency (Cronbach’s α = .95) and moderate-to-strong construct validity as indicated by positive correlations with measures of depression ( r = .42), anxiety ( r = .37), perceived stress ( r = .37), and problematic internet use ( r = .46; all p < .001). Overall, 22% of participants were identified as at risk for PPU. Measurement invariance across gender indicated the scale functioned similarly for males and females. Network analysis further revealed gender-specific symptom patterns, with tolerance emerging as the most central symptom among males and withdrawal most central among females. These findings provide initial validation of the Arabic PPCS and highlight the importance of culturally informed and gender-sensitive approaches to understanding PPU in Arabic-speaking populations.
- 1 July 2026
- Published by Springer Nature in Archives of Sexual Behavior
- Vol. 55 (7) , 3205-3221
Open AccessArabic Validation of the Problematic Pornography Consumption Scale: Psychometric Properties, Measurement Invariance, and Gender-Specific Network Analysis
Problematic pornography use (PPU) remains understudied in Arabic-speaking populations, partly due to the limited availability of culturally validated assessment tools. This study translated and validated the Arabic version of the Problematic Pornography Consumption Scale (PPCS) and examined gender-based differences in symptom structure. A total of 959 Egyptian university students who watched pornography at least once per week (65.1% male, 34.9% female) completed the Arabic PPCS, along with standardized measures of depression, anxiety, perceived stress, and problematic internet use. Confirmatory factor analysis supported the original six-factor model (CFI = 0.950, RMSEA = 0.075, SRMR = 0.031), with the scale demonstrating excellent internal consistency (Cronbach’s α = .95) and moderate-to-strong construct validity as indicated by positive correlations with measures of depression ( r = .42), anxiety ( r = .37), perceived stress ( r = .37), and problematic internet use ( r = .46; all p < .001). Overall, 22% of participants were identified as at risk for PPU. Measurement invariance across gender indicated the scale functioned similarly for males and females. Network analysis further revealed gender-specific symptom patterns, with tolerance emerging as the most central symptom among males and withdrawal most central among females. These findings provide initial validation of the Arabic PPCS and highlight the importance of culturally informed and gender-sensitive approaches to understanding PPU in Arabic-speaking populations.
- Open Access
- 16 September 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-16
The association between H. pylori infection and cognitive deterioration: a systematic review and meta-analysis
Background: The association between cognitive decline and Helicobacter pylori (H. pylori) infection remains controversial, with some evidence suggesting that H. pylori eradication may slow the progression of the disease. This meta-analysis aims to investigate the bidirectional relationship between H. pylori and cognitive decline. Methods: We searched PubMed, Web of Science, the Cochrane Library, and Scopus for double-arm studies that reported either the prevalence of cognitive decline in individuals with H. pylori-positive status or the prevalence of H. pylori infection in patients with cognitive decline. A random-effects meta-analysis was conducted using Comprehensive Meta-Analysis software to pool the odds ratios from the included studies. Study quality was assessed using the Newcastle–Ottawa Scale. Results: Our search identified 1,240 records, with 16 studies meeting the inclusion criteria. Meta-analysis showed that patients with H. pylori had a significantly higher risk of cognitive decline (OR = 1.338, 95% CI 1.046–1.713), with the strongest association seen in studies grouping cognitive dysfunction and dementia (OR: 3.190, 95% CI 1.853–5.490). However, the risk of Alzheimer’s disease was insignificant. Cognitive decline cohorts showed a significantly higher prevalence of H. pylori (OR = 1.5, 95% CI 1.131–1.989), with a significant association with Alzheimer’s disease (OR: 1.630, 95% CI 1.064–2.497), but not with dementia or cognitive dysfunction. The association varied across study designs, with cross-sectional studies showing no association in both analyses. Heterogeneity was substantial (I 2 > 70% in most analyses), highlighting variability in the findings. Conclusion: This meta-analysis indicates a bidirectional association between H. pylori and cognitive decline. While H. pylori infection increased the overall risk of cognitive decline, no significant link was found with Alzheimer's disease. Conversely, Alzheimer’s disease patients had a higher prevalence of H. pylori infection. High heterogeneity underscores the need for further well-designed studies to clarify this relationship.
- 16 September 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-16
Open AccessThe association between H. pylori infection and cognitive deterioration: a systematic review and meta-analysis
Background: The association between cognitive decline and Helicobacter pylori (H. pylori) infection remains controversial, with some evidence suggesting that H. pylori eradication may slow the progression of the disease. This meta-analysis aims to investigate the bidirectional relationship between H. pylori and cognitive decline. Methods: We searched PubMed, Web of Science, the Cochrane Library, and Scopus for double-arm studies that reported either the prevalence of cognitive decline in individuals with H. pylori-positive status or the prevalence of H. pylori infection in patients with cognitive decline. A random-effects meta-analysis was conducted using Comprehensive Meta-Analysis software to pool the odds ratios from the included studies. Study quality was assessed using the Newcastle–Ottawa Scale. Results: Our search identified 1,240 records, with 16 studies meeting the inclusion criteria. Meta-analysis showed that patients with H. pylori had a significantly higher risk of cognitive decline (OR = 1.338, 95% CI 1.046–1.713), with the strongest association seen in studies grouping cognitive dysfunction and dementia (OR: 3.190, 95% CI 1.853–5.490). However, the risk of Alzheimer’s disease was insignificant. Cognitive decline cohorts showed a significantly higher prevalence of H. pylori (OR = 1.5, 95% CI 1.131–1.989), with a significant association with Alzheimer’s disease (OR: 1.630, 95% CI 1.064–2.497), but not with dementia or cognitive dysfunction. The association varied across study designs, with cross-sectional studies showing no association in both analyses. Heterogeneity was substantial (I 2 > 70% in most analyses), highlighting variability in the findings. Conclusion: This meta-analysis indicates a bidirectional association between H. pylori and cognitive decline. While H. pylori infection increased the overall risk of cognitive decline, no significant link was found with Alzheimer's disease. Conversely, Alzheimer’s disease patients had a higher prevalence of H. pylori infection. High heterogeneity underscores the need for further well-designed studies to clarify this relationship.
- Open Access
- 29 January 2025
- Published by Qeios Ltd
Review of: "Investigating the Role of Vitamin D in the Prevention and Control of Dengue Virus Vectors and Related Diseases: A Systematic Review"
DISCREPANCY BETWEEN PROSPERO PROTOCOL AND PUBLISHED ARTICLE The registered PROSPERO protocol (_"Knockdown resistance (kdr) Associated Organochlorine Resistance in Mosquito-Borne Diseases"_) is entirely unrelated to the topic of this systematic revie...
- 29 January 2025
- Published by Qeios Ltd
Open AccessReview of: "Investigating the Role of Vitamin D in the Prevention and Control of Dengue Virus Vectors and Related Diseases: A Systematic Review"
DISCREPANCY BETWEEN PROSPERO PROTOCOL AND PUBLISHED ARTICLE The registered PROSPERO protocol (_"Knockdown resistance (kdr) Associated Organochlorine Resistance in Mosquito-Borne Diseases"_) is entirely unrelated to the topic of this systematic revie...
- Open Access
- 1 August 2023
- Published by Canadian Society of Respiratory Therapists in Canadian Journal of Respiratory Therapy
- Vol. 59 (1) , 154-166
Inhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
Background: More than six million people died due to COVID-19, and 10-15% of infected individuals suffer from post-covid syndrome. Corticosteroids are widely used in the management of severe COVID-19 and post-acute COVID-19 symptoms. This study synthesizes current evidence of the effectiveness of inhaled corticosteroids (ICS) on mortality, hospital length-of-stay (LOS), and improvement of smell scores in patients with COVID-19. Methods: We searched Embase, Web of Science, PubMed, Cochrane Library, and Scopus until Aug 2022. The Cochrane risk of bias tool was used to assess the quality of studies. We evaluated the effectiveness of ICS in COVID-19 patients through measures of mortality, LOS, alleviation of post-acute COVID-19 symptoms, time to sustained self-reported cure, and sense of smell (visual analog scale (VAS)). Results: Ten studies were included in the meta-analysis. Our study showed a significant decrease in the LOS in ICS patients over placebo (MD = -1.52, 95% CI [-2.77 to -0.28], p-value = 0.02). Patients treated with intranasal corticosteroids (INC) showed a significant improvement in VAS smell scores from week three to week four (MD =1.52, 95% CI [0.27 to 2.78], p-value = 0.02), and alleviation of COVID-related symptoms after 14 days (RR = 1.17, 95% CI [1.09 to 1.26], p-value < 0.0001). No significant differences were detected in mortality (RR= 0.69, 95% CI [0.36 to 1.35], p-value = 0.28) and time to sustained self-reported cure (MD = -1.28, 95% CI [-6.77 to 4.20], p-value = 0.65). Conclusion: We concluded that the use of ICS decreased patient LOS and improved COVID-19-related symptoms. INC may have a role in improving the smell score. Therefore, using INC and ICS for two weeks or more may prove beneficial. Current data do not demonstrate an effect on mortality or time to sustained self-reported cure. However, the evidence is inconclusive, and more studies are needed for more precise data.
- 1 August 2023
- Published by Canadian Society of Respiratory Therapists in Canadian Journal of Respiratory Therapy
- Vol. 59 (1) , 154-166
Open AccessInhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
Background: More than six million people died due to COVID-19, and 10-15% of infected individuals suffer from post-covid syndrome. Corticosteroids are widely used in the management of severe COVID-19 and post-acute COVID-19 symptoms. This study synthesizes current evidence of the effectiveness of inhaled corticosteroids (ICS) on mortality, hospital length-of-stay (LOS), and improvement of smell scores in patients with COVID-19. Methods: We searched Embase, Web of Science, PubMed, Cochrane Library, and Scopus until Aug 2022. The Cochrane risk of bias tool was used to assess the quality of studies. We evaluated the effectiveness of ICS in COVID-19 patients through measures of mortality, LOS, alleviation of post-acute COVID-19 symptoms, time to sustained self-reported cure, and sense of smell (visual analog scale (VAS)). Results: Ten studies were included in the meta-analysis. Our study showed a significant decrease in the LOS in ICS patients over placebo (MD = -1.52, 95% CI [-2.77 to -0.28], p-value = 0.02). Patients treated with intranasal corticosteroids (INC) showed a significant improvement in VAS smell scores from week three to week four (MD =1.52, 95% CI [0.27 to 2.78], p-value = 0.02), and alleviation of COVID-related symptoms after 14 days (RR = 1.17, 95% CI [1.09 to 1.26], p-value < 0.0001). No significant differences were detected in mortality (RR= 0.69, 95% CI [0.36 to 1.35], p-value = 0.28) and time to sustained self-reported cure (MD = -1.28, 95% CI [-6.77 to 4.20], p-value = 0.65). Conclusion: We concluded that the use of ICS decreased patient LOS and improved COVID-19-related symptoms. INC may have a role in improving the smell score. Therefore, using INC and ICS for two weeks or more may prove beneficial. Current data do not demonstrate an effect on mortality or time to sustained self-reported cure. However, the evidence is inconclusive, and more studies are needed for more precise data.